Overview
Antiretroviral Therapy and Cardiovascular Risks in HIV
Prevention of HIV-related Cardiovascular Disease: An eNewsletter Series
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This text-based eNewsletter is the third in a four-part series. It reviews the benefits of antiretroviral therapy on cardiovascular risks and selection of therapy for HIV-infected individuals with dyslipidemia. Short audio commentary provided by Dr. Edgar Turner Overton compliments text and provides practical information.
Use the "Ask The Expert" button (available when logged in) to submit a question to Dr. Overton. Responses will be posted to the "Discussion Board", be sure to check back to review ongoing discussions.
Use the "Ask The Expert" button (available when logged in) to submit a question to Dr. Overton. Responses will be posted to the "Discussion Board", be sure to check back to review ongoing discussions.
This educational activity is designed for cardiologists, infectious disease specialists, primary care physicians, and other clinicians interested in the management of patients with HIV-related cardiovascular disease.
The use of ART reduces CVD risks in HIV-infected individuals. Yet, many patients develop lipid abnormalities that require a change in therapy or addition of lipid-lowering therapy. Clinicians must be familiar with available data to select therapies and avoid complications for their patients.
Upon completion of this activity, participants will be able to:
• Evaluate potential drug interactions between cardiovascular medications and ART, as well as CVD-related adverse effects of certain ART
• Identify the most appropriate statins for patients with HIV and CVD risk factors based on their current ART
• Evaluate potential drug interactions between cardiovascular medications and ART, as well as CVD-related adverse effects of certain ART
• Identify the most appropriate statins for patients with HIV and CVD risk factors based on their current ART
This activity is supported by an educational grant from Gilead Sciences, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Edgar Turner Overton, MD
Associate Professor of Medicine
Medical Director
University of Alabama at Birmingham
Associate Professor of Medicine
Medical Director
University of Alabama at Birmingham
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationship has been provided:
Edgar Turner Overton, MD (Faculty)
Research Support: Gilead Sciences, Inc., ViiV Healthcare
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
Michael Yin, MD (Peer Reviewer)
Type of financial relationship(s): None
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pre-test, view the eNewsletter and complete the post-test and evaluation. To receive credit, 66% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
